Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
在 EVOLVE 研究中,通过循环肿瘤 DNA 识别 PARP 抑制剂进展时卵巢癌的 Cediranib 联合 Olaparib 的耐药机制,这是一项 II 期试验。
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-0797
Lheureux, Stephanie; Prokopec, Stephenie D; Oldfield, Leslie E; Gonzalez-Ochoa, Eduardo; Bruce, Jeffrey P; Wong, Derek; Danesh, Arnavaz; Torti, Dax; Torchia, Jonathan; Fortuna, Alexander; Singh, Sharanjit; Irving, Matthew; Marsh, Kayla; Lam, Bernard; Speers, Vanessa; Yosifova, Aleksandra; Oaknin, Ana; Madariaga, Ainhoa; Dhani, Neesha C; Bowering, Valerie; Oza, Amit M; Pugh, Trevor J